Walleye Capital
RAPP

Walleye Capital’s Rapport Therapeutics RAPP Stock Holding History

Walleye Capital’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.26M Buy
102,163
+91,015
+816% +$3.35M 0.02% 928
2026
Q1 		$349K Buy
+11,148
New +$314K ﹤0.01% 2948
2025
Q4 		– Sell
-69,570
Closed -$2.07M – 5236
2025
Q3 		$2.07M Buy
+69,570
New +$1.24M 0.01% 1555

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Walleye Capital's RAPP Position: Q2 2026 in Review

Walleye Capital increased its Rapport Therapeutics (RAPP) stake by 816% in Q2 2026, buying an estimated $3.35M and bringing the position to 102,163 shares worth $4.26M. The position accounts for 0.02% of the portfolio, ranked #928.

Walleye Capital first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Walleye Capital held 102,163 shares of Rapport Therapeutics worth $4.26M as of Q2 2026.
  • Walleye Capital bought 91,015 Rapport Therapeutics shares in Q2 2026, an estimated $3.35M.
  • Rapport Therapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #928 holding.
  • Walleye Capital first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.